We have to separate the science from the management. Although it does not feel like it because of the slow rate of progress and our discontent with the management, the prospects are actually better now than a couple of years ago. Let's not forget BETonMACE only just missed being positive (and perhaps some of the bigger companies with more muscle would have persuaded the FDA it actually was positive considering the HF results), we have got BT status, and we've got exciting preclinical covid data. And we're still sitting on some very promising HIV data.
If I had more cash I'd be scooping up more of these underpriced shares.